2022
DOI: 10.7759/cureus.22367
|View full text |Cite
|
Sign up to set email alerts
|

Rheumatoid Arthritis and Associated Lung Diseases: A Comprehensive Review

Abstract: Rheumatoid arthritis (RA) is a prevalent autoimmune disorder affecting 0.5-1% of the population in North America and Europe. Pulmonary manifestations in rheumatoid arthritis patients result in significant morbidity and mortality. Management of these pulmonary manifestations in RA patients causes various challenges for the physicians. This review article has discussed the current state of knowledge of these pulmonary manifestations, including interstitial lung diseases, airway-related diseases, pulmonary vascul… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 83 publications
0
4
0
Order By: Relevance
“…The result is the destruction of joint structure, and the inflammation of the synovial membrane by several immune cells, including macrophages, T and B cells, as well as the cytokines and matrix metalloproteinases (MMPs) released by them [ 1 ]. The progression of the illness can cause the systemic involvement of cardiovascular [ 2 , 3 ], respiratory [ 4 ], and renal tissue [ 5 ]. A basic determinant in RA diagnosis is the presence of rheumatoid factors (RFs) and anti-citrullinated peptide antibodies (ACPAs).…”
Section: Introductionmentioning
confidence: 99%
“…The result is the destruction of joint structure, and the inflammation of the synovial membrane by several immune cells, including macrophages, T and B cells, as well as the cytokines and matrix metalloproteinases (MMPs) released by them [ 1 ]. The progression of the illness can cause the systemic involvement of cardiovascular [ 2 , 3 ], respiratory [ 4 ], and renal tissue [ 5 ]. A basic determinant in RA diagnosis is the presence of rheumatoid factors (RFs) and anti-citrullinated peptide antibodies (ACPAs).…”
Section: Introductionmentioning
confidence: 99%
“…Respiratory system involvement usually appears in the first 5 years of RA diagnosis as interstitial lung disease, pleural effusion, pleuritis, or rheumatoid pulmonary nodules 6,7–9,11 . Of all the respiratory EAMs, rheumatoid pulmonary nodules are rarest 12–14 .…”
Section: Introductionmentioning
confidence: 99%
“…3 Respiratory system involvement usually appears in the first 5 years of RA diagnosis as interstitial lung disease, pleural effusion, pleuritis, or rheumatoid pulmonary nodules. 6,[7][8][9]11 Of all the respiratory EAMs, rheumatoid pulmonary nodules are rarest. [12][13][14] For example, Kondo and colleagues mention a 75-year-old female patient with rheumatoid lung nodules on etanercept treatment.…”
mentioning
confidence: 99%
“…Interstitial lung disease in RA includes usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP); RA patients with UIP are associated with a poor prognosis [5]. AD is also frequently detected in RA [6][7][8][9] and worsens its prognosis [10,11]. Thus, it is necessary to clarify the pathogenesis of interstitial lung disease and AD in RA.…”
Section: Introductionmentioning
confidence: 99%